Last reviewed · How we verify
Hepatitis B vaccination
Hepatitis B vaccination stimulates the immune system to produce antibodies and cellular immunity against hepatitis B virus surface antigen, preventing infection and disease.
Hepatitis B vaccination stimulates the immune system to produce antibodies and cellular immunity against hepatitis B virus surface antigen, preventing infection and disease. Used for Prevention of hepatitis B virus infection and chronic hepatitis B disease.
At a glance
| Generic name | Hepatitis B vaccination |
|---|---|
| Sponsor | Tel-Aviv Sourasky Medical Center |
| Drug class | vaccine |
| Target | Hepatitis B surface antigen (HBsAg) |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
The vaccine contains hepatitis B surface antigen (HBsAg), typically produced via recombinant DNA technology, which triggers both humoral (antibody) and cell-mediated immune responses. This priming of the adaptive immune system enables rapid recognition and neutralization of hepatitis B virus upon exposure, preventing viral infection and chronic disease development.
Approved indications
- Prevention of hepatitis B virus infection and chronic hepatitis B disease
Common side effects
- Injection site pain, redness, or swelling
- Fatigue
- Headache
- Myalgia
- Low-grade fever
Key clinical trials
- INTEGRA: A Vanguard Study of Health Service Delivery in a Mobile Health Delivery Unit (NA)
- Dose-Escalating Study of Pfs230D1 in Combination With R21 in Matrix-M in African Adults (PHASE1)
- BEATRIX: A Study to Learn About a Group B Streptococcus Vaccine in Healthy Pregnant Women and Their Babies (PHASE3)
- Managing Hepatitis B (Hep. B) and Human Papilloma Virus (HPV) Related Cancers and Mental Health. (PHASE4)
- Immunogenicity of 2 Versus 3 Doses of Combined Hepatitis B Vaccines in 2-18 Months Old Children (PHASE4)
- Project SPEED - Streamlined Protocol for Early Engagement and Delivery of HIV Prevention With Long-acting Injectable Cabotegravir: A Nurse-driven Protocol (NA)
- Investigation of the Effects of Early Skin-to-Skin Contact on Mother and Baby in Cesarean Births (NA)
- RTSS Vaccine and PBO Net Impact on Malaria Infection and Transmission in Malawi
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |